Table 6.
Treatment response before and after biologic therapy.
| Variables | Dupilumab | Mepolizumab | Omalizumab | Benralizumab | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n=12 (%) | n=53 (%) | n=22 (%) | n=10 (%) | |||||||||
| Before | After | Before | After | Before | After | Before | After | |||||
| Eosinophil (cells/μl) | 817.1±456.3 | 222.1±124.6 | 768.3±433.6 | 187.1±114.0 | 330.2±248.3 | 177.3±130.7 | 966.0±478.3 | 101.5±127.7 | ||||
| p | <0.001* | <0.001* | 0.047* | <0.001* | ||||||||
| FEV1% | 68.7±17.2 | 82.5±11.0 | 59.6±12.3 | 75.4±10.7 | 55.7±11.2 | 77.1±8.0 | 52.0±5.6 | 68.0±7.4 | ||||
| p | 0.024* | <0.001* | <0.001* | <0.001* | ||||||||
| Exacerbations / year | ||||||||||||
| Total | 11 | 2 | ||||||||||
| (91.7) | (16.7) | 46 | 7 | 15 | 5 | 10 | 0 | |||||
| p | 0.001* | (86.8) | (13.2) | (68.2) | (22.7) | (100.0) | (0.0) | |||||
| Average | 2.6±1.6 | 0.25±0.62 | <0.001* | 0.006* | <0.001* | |||||||
| p | <0.001* | <0.001* | 2.1±1.72 | 0.12±0.3 | 3.1±2.2 | 0.5±0.91 | 2.5±1.4 | 0 | ||||
| Oral corticosteroid | <0.001* | <0.001* | ||||||||||
| Total | 6 | 0 | <0.001* | |||||||||
| (50.0) | (0.0) | 45 | 5 | 14 | 5 | 10 | 0 | |||||
| p | 0.014* | (84.9) | (9.4) | (63.6) | (22.7) | (100.0) | (0.0) | |||||
| Average | 3.8±2.1 | 0 | <0.001* | 0.014* | <0.001* | |||||||
| p | <0.001* | 5.8±6.2 | 0.75±1.3 | 4.9±3.1 | 1.1±1.8 | 7.1±6.4 | 0 | |||||
| <0.001* | <0.001* | |||||||||||
Values presented as mean ± SD were analyzed by Wilcoxon test; values presented as number and percent were analyzed by Fischer Exact test; *significant.